Related Experiment Videos
Semen quality before and after gonadotoxic treatment
G Bahadur1, O Ozturk, A Muneer
1Fertility and Reproductive Medicine Laboratories, Department of Obstetrics and Gynaecology, Royal Free and University College Medical School, University College Hospitals Trust, Rosenheim Building, 25 Grafton Way, London WC1E 6DB, UK. g.bahadur@ucl.ac.uk
Human Reproduction (Oxford, England)
|February 4, 2005
Summary
Gonadotoxic therapy significantly reduces sperm quality, impacting sperm concentration and motility. Cancer type and pre-treatment sperm counts are key factors influencing recovery, underscoring the need for sperm banking.
Area of Science:
- Reproductive Medicine
- Oncology
- Andrology
Background:
- Gonadotoxic therapies are used to treat various cancers and other conditions.
- These treatments can adversely affect male reproductive function.
- Assessing the impact on semen quality is crucial for patient counseling and fertility preservation.
Purpose of the Study:
- To analyze changes in semen quality in patients before and after gonadotoxic therapy.
- To identify factors influencing semen quality recovery after treatment.
- To evaluate the necessity of sperm banking across different diagnostic categories.
Main Methods:
- Retrospective analysis of semen quality in 314 patients over 26 years.
- Categorization of patients by diagnosis: leukemia, lymphoma, testicular cancer, benign conditions, and other neoplasms.
- Assessment of sperm concentration, motility, and semen volume, and analysis of azoospermia/oligospermia incidence and recovery patterns.
Main Results:
- Significant reductions in post-treatment sperm concentration, motility, and semen volume were observed across the cohort.
- Patients with testicular cancer showed lower pre-treatment sperm counts but better post-treatment azoospermia rates compared to lymphoma and leukemia patients.
- The diagnostic category was the primary predictor of post-treatment azoospermia, with limited significant recovery of gonadal function observed.
Conclusions:
- Gonadotoxic treatment leads to significant declines in semen quality.
- Cancer type and baseline sperm concentration are critical determinants of post-treatment semen quality and spermatogenesis recovery.
- Sperm banking is highly recommended before gonadotoxic therapy, even for patients with benign conditions, due to unpredictable outcomes and limited recovery potential.